基本信息

产品名称	HDAC4 Mouse mAb
别名	组蛋白去乙酰化酶4抗体 \| 组蛋白去乙酰化酶4重组兔单抗 \| HDAC4小鼠单克隆抗体 \| HDAC4小鼠单抗
英文别名	AHO3 antibody \| BDMR antibody \| EC 3.5.1.98 antibody \| HA6116 antibody \| HD 4 antibody \| HD4 antibody \| HDAC 4 antibody \| HDAC A antibody \| HDAC4 antibody \| HDAC4_HUMAN antibody \| HDACA antibody \| Histone deacetylase 4 antibody \| Histone Deacetylase A ant
规格或纯度	ExactAb™, Validated, 1.0 mg/mL
宿主种属	小鼠(Mouse)
特异性	HDAC4
种属反应性	人(Human),大鼠(Rat),小鼠(Mouse),猴(Monkey)
免疫原	Recombinant protein of human HDAC4 (AA 11-125)
阳性对照	WB: Jurkat, NIH/3T3 and C6 cell lysates. IP: HeLa lysates.
偶联	Unconjugated

产品属性

克隆类型	单克隆抗体
克隆号	4A3-H7-C6
Format	Whole IgG
亚型	Mouse IgG2a
轻链亚型	kappa
SDS-PAGE	150 kDa
纯化方法	Protein G purified
物理外观	Liquid
储存缓冲液	10mM PBS, 50% Glycerol, 0.5% BSA, 0.02% Sodium azide, pH 7.3
防腐剂	0.02% Sodium azide
浓度	1.0 mg/mL
储存温度	-20°C储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	4°C 短期储存（1-2 周）。-20°C下长期保存（24个月）。收货后建议分装。避免冷冻/解冻循环。
分子类型	抗体

关联靶点（人）

HDAC4 Tclin 组蛋白去乙酰化酶4(Histone deacetylase 4) (0 活性数据)

点击查看靶蛋白信息： HDAC4

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

HDAC4 Tclin Histone deacetylase 4 (2328 活性数据)

点击查看靶蛋白信息： HDAC4

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

HDAC4 Tclin Cereblon/Histone deacetylase 4 (8 活性数据)

点击查看靶蛋白信息： HDAC4

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

图片

Western Blot: HDAC4 Mouse mAb (Ab107057)

HDAC4 Mouse mAb (Ab107057) - Western Blot
All lanes: HDAC4 Mouse mAb (Ab107057) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Mouse IgG H&L (HRP) (Ab179001) at 1/20000 dilution

Predicted band size: 119 kDa
Observed band size: 134 kDa
Exposure time: 60.0 s

Western Blot: HDAC4 Mouse mAb (Ab107057)

HDAC4 Mouse mAb (Ab107057) - Western Blot
Immunoprecipitation analysis of HDAC4 in HeLa lysates using HDAC4 Mouse mAb (Ab107057)

应用

应用名称	稀释比例
WB	1/500-1/1000
IP	1/20

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到2个结果

批号(Lot Number)	证书类型	货号
ZJ24F0404334	分析证书	Ab107057
ZJ24F0404335	分析证书	Ab107057

技术文档和文章

蛋白质印迹的一抗选择指南

Categories: 实验方案（Protocols）

探索主题:

重组抗体单克隆抗体多克隆抗体蛋白质印迹内参抗体一抗选择

Guidelines of Primary Antibodies for Western Blotting

Categories: 实验方案（Protocols）

探索主题:

Western blotting Monoclonal antibodies Recombinant Antibodies Polyclonal Antibodies Primary Antibodies Selection Loading Controls

Guidelines of Primary Antibodies for Western Blotting

Categories: 实验方案（Protocols）

探索主题:

Western blotting Monoclonal antibodies Recombinant Antibodies Polyclonal Antibodies Primary Antibodies Selection Loading Controls

高分子量蛋白质印迹法

Categories: 实验方案（Protocols）

探索主题:

免疫印迹生物缓冲液蛋白质印迹高分子量蛋白大分子蛋白蛋白质电泳 WB抗体

Protocol of Western Blotting For High Molecular Weights

Categories: 实验方案（Protocols）

探索主题:

Western blotting Biological buffer Immunoblotting Protein Electrophoresis High Molecular Weights large molecular proteins WB antibody

Protocol of Western Blotting For High Molecular Weights

Categories: 实验方案（Protocols）

探索主题:

Western blotting Biological buffer Immunoblotting Protein Electrophoresis High Molecular Weights large molecular proteins WB antibody

Protocol of Western Blotting For High Molecular Weights

Categories: 实验方案（Protocols）

探索主题:

Western blotting Biological buffer Immunoblotting Protein Electrophoresis High Molecular Weights large molecular proteins WB antibody

Protocol of Western Blotting For High Molecular Weights

Categories: 实验方案（Protocols）

探索主题:

Western blotting Biological buffer Immunoblotting Protein Electrophoresis High Molecular Weights large molecular proteins WB antibody

免疫沉淀通用实验方案

Categories: 实验方案（Protocols）

探索主题:

免疫沉淀蛋白质印迹细胞裂解液免疫共沉淀 IP 蛋白质互作蛋白A/G磁珠

General Immunoprecipitation Protocol

Categories: 实验方案（Protocols）

探索主题:

Immunoprecipitation Western blot Cell lysate IP Co-immunoprecipitation Protein interaction Protein A/G magnetic beads

General Immunoprecipitation Protocol

Categories: 实验方案（Protocols）

探索主题:

Immunoprecipitation Western blot Cell lysate IP Co-immunoprecipitation Protein interaction Protein A/G magnetic beads

General Immunoprecipitation Protocol

Categories: 实验方案（Protocols）

探索主题:

Immunoprecipitation Western blot Cell lysate IP Co-immunoprecipitation Protein interaction Protein A/G magnetic beads

General Immunoprecipitation Protocol

Categories: 实验方案（Protocols）

探索主题:

Immunoprecipitation Western blot Cell lysate IP Co-immunoprecipitation Protein interaction Protein A/G magnetic beads

RNA免疫沉淀方案

Categories: 实验方案（Protocols）

探索主题:

交联 IP 蛋白A/G磁珠 RNA免疫沉淀 RIP RNA蛋白质互作同种型对照抗体 Input

RNA Immunoprecipitation (RIP) Protocol

Categories: 实验方案（Protocols）

探索主题:

IP Protein A/G magnetic beads RIP Input RNA immunoprecipitation RNA protein interaction Isotype control antibody Crosslinking

RNA Immunoprecipitation (RIP) Protocol

Categories: 实验方案（Protocols）

探索主题:

IP Protein A/G magnetic beads RIP Input RNA immunoprecipitation RNA protein interaction Isotype control antibody Crosslinking

固定免疫沉淀实验方案

Categories: 实验方案（Protocols）

探索主题:

免疫沉淀蛋白质印迹 WB IP 蛋白质互作固定免疫沉淀固定化抗体

Immobilized IP Protocol

Categories: 实验方案（Protocols）

探索主题:

Immunoprecipitation WB Western blot IP Protein interaction Immobilization immunoprecipitation Immobilized antibody

Immobilized IP Protocol

Categories: 实验方案（Protocols）

探索主题:

Immunoprecipitation WB Western blot IP Protein interaction Immobilization immunoprecipitation Immobilized antibody

此产品的引用文献

如何在您的发表作品中引用阿拉丁的产品和网站? 引用文献检索

引用文献

1. Wang H, Lim ZY, Zhou Y, Ng M, Lu T, Lee K, Sangthongpitag K, Goh KC, Wang X, Wu X et al.. (2010) Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.. Bioorg Med Chem Lett, 20 (11): (3314-21). [PMID:20451378]
2. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R. (2010) Chemical phylogenetics of histone deacetylases.. Nat Chem Biol, 6 (3): (238-243). [PMID:20139990]
3. Grozinger CM, Hassig CA, Schreiber SL. (1999) Three proteins define a class of human histone deacetylases related to yeast Hda1p.. Proc Natl Acad Sci USA, 96 (9): (4868-73). [PMID:10220385]
4. Kalin JH, Bergman JA. (2013) Development and therapeutic implications of selective histone deacetylase 6 inhibitors.. J Med Chem, 56 (16): (6297-313). [PMID:23627282]
5. Fass DM, Shah R, Ghosh B, Hennig K, Norton S, Zhao WN, Reis SA, Klein PS, Mazitschek R, Maglathlin RL et al.. (2010) Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin.. ACS Med Chem Lett, 2 (1): (39-42). [PMID:21874153]
6. Arts J, King P, Mariën A, Floren W, Beliën A, Janssen L, Pilatte I, Roux B, Decrane L, Gilissen R et al.. (2009) JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.. Clin Cancer Res, 15 (22): (6841-51). [PMID:19861438]
7. Bergman JA, Woan K, Perez-Villarroel P, Villagra A, Sotomayor EM, Kozikowski AP. (2012) Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.. J Med Chem, 55 (22): (9891-9). [PMID:23009203]
8. Pavlik CM, Wong CY, Ononye S, Lopez DD, Engene N, McPhail KL, Gerwick WH, Balunas MJ. (2013) Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp.. J Nat Prod, 76 (11): (2026-33). [PMID:24164245]
9. Isaacs JT, Antony L, Dalrymple SL, Brennen WN, Gerber S, Hammers H, Wissing M, Kachhap S, Luo J, Xing L et al.. (2013) Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment.. Cancer Res, 73 (4): (1386-99). [PMID:23149916]
10. Cai X, Zhai HX, Wang J, Forrester J, Qu H, Yin L, Lai CJ, Bao R, Qian C. (2010) Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.. J Med Chem, 53 (5): (2000-9). [PMID:20143778]
11. Migliore M, Habrant D, Sasso O, Albani C, Bertozzi SM, Armirotti A, Piomelli D, Scarpelli R. (2016) Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies.. Eur J Med Chem, 109 (216-37). [PMID:26774927]
12. Ellis JD, Neil DA, Inston NG, Jenkinson E, Drayson MT, Hampson P, Shuttleworth SJ, Ready AR, Cobbold M. (2016) Inhibition of Histone Deacetylase 6 Reveals a Potent Immunosuppressant Effect in Models of Transplantation.. Transplantation, 100 (8): (1667-74). [PMID:27222932]
13. Sellmer A, Stangl H, Beyer M, Grünstein E, Leonhardt M, Pongratz H, Eichhorn E, Elz S, Striegl B, Jenei-Lanzl Z et al.. (2018) Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.. J Med Chem, 61 (8): (3454-3477). [PMID:29589441]
14. Shen S, Hadley M, Ustinova K, Pavlicek J, Knox T, Noonepalle S, Tavares MT, Zimprich CA, Zhang G, Robers MB et al.. (2019) Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models.. J Med Chem, 62 (18): (8557-8577). [PMID:31414801]
15. Wang C, Schroeder FA, Wey HY, Borra R, Wagner FF, Reis S, Kim SW, Holson EB, Haggarty SJ, Hooker JM. (2014) In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs.. J Med Chem, 57 (19): (7999-8009). [PMID:25203558]
16. Mai A, Massa S, Pezzi R, Simeoni S, Rotili D, Nebbioso A, Scognamiglio A, Altucci L, Loidl P, Brosch G. (2005) Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.. J Med Chem, 48 (9): (3344-53). [PMID:15857140]
17. Noonepalle S, Shen S, Ptáček J, Tavares MT, Zhang G, Stránský J, Pavlíček J, Ferreira GM, Hadley M, Pelaez G et al.. (2020) Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models.. J Med Chem, 63 (18): (10246-10262). [PMID:32815366]
18. Kevin A Harvey,Zhidong Xu,Phillip Whitley,V Jo Davisson,Rafat A Siddiqui. (2010-02-16) Characterization of anticancer properties of 2,6-diisopropylphenol-docosahexaenoate and analogues in breast cancer cells.. Bioorganic & medicinal chemistry, 18 ((5)): (1866-1874). [PMID:20153203]
19. Marc Lamblin,Russell Spingarn,Tian-Tian Wang,Melanie C Burger,Basel Dabbas,Nicolas Moitessier,John H White,James L Gleason. (2010-10-05) An o-aminoanilide analogue of 1α,25-dihydroxyvitamin D(3) functions as a strong vitamin D receptor antagonist.. Journal of medicinal chemistry, 53 ((20)): (7461-7465). [PMID:20883026]
20. Biyin Cao,Jie Li,Jingyu Zhu,Mingyun Shen,Kunkun Han,Zubin Zhang,Yang Yu,Yali Wang,Depei Wu,Suning Chen,Aining Sun,Xiaowen Tang,Yun Zhao,Chunhua Qiao,Tingjun Hou,Xinliang Mao. (2013-10-12) The antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity.. The Journal of biological chemistry, 288 ((47)): (34181-34189). [PMID:24114842]
21. Jianguo Wang,Shawn A Mahmud,Peter B Bitterman,Yuqing Huo,Arne Slungaard. (2007-08-07) Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.. The Journal of biological chemistry, 282 ((39)): (28408-28418). [PMID:17675290]
22. Kunal Nepali,Ting-Yu Chang,Mei-Jung Lai,Kai-Cheng Hsu,Yun Yen,Tony Eight Lin,Sung-Bau Lee,Jing-Ping Liou. (2020-04-24) Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors.. European journal of medicinal chemistry, 196 (112291-112291). [PMID:32325365]
23. Mai A, Massa S, Rotili D, Simeoni S, Ragno R, Botta G, Nebbioso A, Miceli M, Altucci L, Brosch G.. (2006) Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors.. J Med Chem, 49 (20): (6046-6056). [PMID:17004718] [10.1021/jm0605536]
24. Pérez-Balado C, Nebbioso A, Rodríguez-Graña P, Minichiello A, Miceli M, Altucci L, de Lera AR.. (2007) Bispyridinium dienes: histone deacetylase inhibitors with selective activities.. J Med Chem, 50 (10): (2497-2505). [PMID:17447750] [10.1021/jm070028m]
25. Shi Y, Gerritsma D, Bowes AJ, Capretta A, Werstuck GH.. (2007) Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition.. Bioorg Med Chem Lett, 17 (16): (4491-4494). [PMID:17566732] [10.1016/j.bmcl.2007.06.006]
26. Itoh Y, Suzuki T, Kouketsu A, Suzuki N, Maeda S, Yoshida M, Nakagawa H, Miyata N.. (2007) Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.. J Med Chem, 50 (22): (5425-5438). [PMID:17929798] [10.1021/jm7009217]
27. Wilson KJ, Witter DJ, Grimm JB, Siliphaivanh P, Otte KM, Kral AM, Fleming JC, Harsch A, Hamill JE, Cruz JC, Chenard M, Szewczak AA, Middleton RE, Hughes BL, Dahlberg WK, Secrist JP, Miller TA.. (2008) Phenylglycine and phenylalanine derivatives as potent and selective HDAC1 inhibitors (SHI-1).. Bioorg Med Chem Lett, 18 (6): (1859-1863). [PMID:18304810] [10.1016/j.bmcl.2008.02.012]
28. Lahm A, Paolini C, Pallaoro M, Nardi MC, Jones P, Neddermann P, Sambucini S, Bottomley MJ, Lo Surdo P, Carfí A, Koch U, De Francesco R, Steinkühler C, Gallinari P.. (2007) Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases.. Proc Natl Acad Sci U S A, 104 (44): (17335-17340). [PMID:17956988] [10.1073/pnas.0706487104]
29. Campbell CT, Aich U, Weier CA, Wang JJ, Choi SS, Wen MM, Maisel K, Sampathkumar SG, Yarema KJ.. (2008) Targeting pro-invasive oncogenes with short chain fatty acid-hexosamine analogues inhibits the mobility of metastatic MDA-MB-231 breast cancer cells.. J Med Chem, 51 (24): (8135-8147). [PMID:19053749] [10.1021/jm800873k]
30. Oyelere AK, Chen PC, Guerrant W, Mwakwari SC, Hood R, Zhang Y, Fan Y.. (2009) Non-peptide macrocyclic histone deacetylase inhibitors.. J Med Chem, 52 (2): (456-468). [PMID:19093884] [10.1021/jm801128g]
31. Mahboobi S, Dove S, Sellmer A, Winkler M, Eichhorn E, Pongratz H, Ciossek T, Baer T, Maier T, Beckers T.. (2009) Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.. J Med Chem, 52 (8): (2265-2279). [PMID:19301902] [10.1021/jm800988r]
32. Charrier C, Clarhaut J, Gesson JP, Estiu G, Wiest O, Roche J, Bertrand P.. (2009) Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression.. J Med Chem, 52 (9): (3112-3115). [PMID:19385600] [10.1021/jm9002439]
33. Dallavalle S, Cincinelli R, Nannei R, Merlini L, Morini G, Penco S, Pisano C, Vesci L, Barbarino M, Zuco V, De Cesare M, Zunino F.. (2009) Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.. Eur J Med Chem, 44 (5): (1900-1912). [PMID:19084294] [10.1016/j.ejmech.2008.11.005]
34. Casero RA, Woster PM.. (2009) Recent advances in the development of polyamine analogues as antitumor agents.. J Med Chem, 52 (15): (4551-4573). [PMID:19534534] [10.1021/jm900187v]
35. Hu F, Chou CJ, Gottesfeld JM.. (2009) Design and synthesis of novel hybrid benzamide-peptide histone deacetylase inhibitors.. Bioorg Med Chem Lett, 19 (14): (3928-3931). [PMID:19362838] [10.1016/j.bmcl.2009.03.085]
36. Olsen CA, Ghadiri MR.. (2009) Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides.. J Med Chem, 52 (23): (7836-7846). [PMID:19705846] [10.1021/jm900850t]
37. Desai D, Salli U, Vrana KE, Amin S.. (2010) SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors.. Bioorg Med Chem Lett, 20 (6): (2044-2047). [PMID:20167479] [10.1016/j.bmcl.2009.07.068]
38. Lamblin M, Dabbas B, Spingarn R, Mendoza-Sanchez R, Wang TT, An BS, Huang DC, Kremer R, White JH, Gleason JL.. (2010) Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids.. Bioorg Med Chem, 18 (11): (4119-4137). [PMID:20452225] [10.1016/j.bmc.2010.03.078]
39. Mwakwari SC, Guerrant W, Patil V, Khan SI, Tekwani BL, Gurard-Levin ZA, Mrksich M, Oyelere AK.. (2010) Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.. J Med Chem, 53 (16): (6100-6111). [PMID:20669972] [10.1021/jm100507q]
40. Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, Gottesfeld JM.. (2006) Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.. Nat Chem Biol, 2 (10): (551-558). [PMID:16921367] [10.1038/nchembio815]
41. Hutt DM, Herman D, Rodrigues AP, Noel S, Pilewski JM, Matteson J, Hoch B, Kellner W, Kelly JW, Schmidt A, Thomas PJ, Matsumura Y, Skach WR, Gentzsch M, Riordan JR, Sorscher EJ, Okiyoneda T, Yates JR, Lukacs GL, Frizzell RA, Manning G, Gottesfeld JM, Balch WE.. (2010) Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.. Nat Chem Biol, 6 (1): (25-33). [PMID:19966789] [10.1038/nchembio.275]
42. Mahboobi S, Sellmer A, Winkler M, Eichhorn E, Pongratz H, Ciossek T, Baer T, Maier T, Beckers T.. (2010) Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.. J Med Chem, 53 (24): (8546-8555). [PMID:21080629] [10.1021/jm100665z]
43. Zhang Y, Feng J, Jia Y, Wang X, Zhang L, Liu C, Fang H, Xu W.. (2011) Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.. J Med Chem, 54 (8): (2823-2838). [PMID:21476600] [10.1021/jm101605z]
44. Kemp MM, Wang Q, Fuller JH, West N, Martinez NM, Morse EM, Weïwer M, Schreiber SL, Bradner JE, Koehler AN.. (2011) A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold.. Bioorg Med Chem Lett, 21 (14): (4164-4169). [PMID:21696956] [10.1016/j.bmcl.2011.05.098]
45. Wang C, Henkes LM, Doughty LB, He M, Wang D, Meyer-Almes FJ, Cheng YQ.. (2011) Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities.. J Nat Prod, 74 (10): (2031-2038). [PMID:21793558] [10.1021/np200324x]
46. Singh RK, Mandal T, Balsubramanian N, Viaene T, Leedahl T, Sule N, Cook G, Srivastava DK.. (2011) Histone deacetylase activators: N-acetylthioureas serve as highly potent and isozyme selective activators for human histone deacetylase-8 on a fluorescent substrate.. Bioorg Med Chem Lett, 21 (19): (5920-5923). [PMID:21865040] [10.1016/j.bmcl.2011.07.093]
47. Choi SE, Weerasinghe SV, Pflum MK.. (2011) The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.. Bioorg Med Chem Lett, 21 (20): (6139-6142). [PMID:21889343] [10.1016/j.bmcl.2011.08.027]
48. Klausmeyer P, Shipley SM, Zuck KM, McCloud TG.. (2011) Histone deacetylase inhibitors from Burkholderia thailandensis.. J Nat Prod, 74 (10): (2039-2044). [PMID:21967146] [10.1021/np200532d]
49. Neelarapu R, Holzle DL, Velaparthi S, Bai H, Brunsteiner M, Blond SY, Petukhov PA.. (2011) Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.. J Med Chem, 54 (13): (4350-4364). [PMID:21548582] [10.1021/jm2001025]
50. Kelly JM, Taylor MC, Horn D, Loza E, Kalvinsh I, Björkling F.. (2012) Inhibitors of human histone deacetylase with potent activity against the African trypanosome Trypanosoma brucei.. Bioorg Med Chem Lett, 22 (5): (1886-1890). [PMID:22326398] [10.1016/j.bmcl.2012.01.072]
51. Hutt DM, Olsen CA, Vickers CJ, Herman D, Chalfant M, Montero A, Leman LJ, Burkle R, Maryanoff BE, Balch WE, Ghadiri MR.. (2011) Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.. ACS Med Chem Lett, 2 (9): (703-707). [PMID:21984958] [10.1021/ml200136e]
52. Guerrant W, Patil V, Canzoneri JC, Oyelere AK.. (2012) Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.. J Med Chem, 55 (4): (1465-1477). [PMID:22260166] [10.1021/jm200799p]
53. Lai MJ, Huang HL, Pan SL, Liu YM, Peng CY, Lee HY, Yeh TK, Huang PH, Teng CM, Chen CS, Chuang HY, Liou JP.. (2012) Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo.. J Med Chem, 55 (8): (3777-3791). [PMID:22439863] [10.1021/jm300197a]
54. Suzuki T, Khan MN, Sawada H, Imai E, Itoh Y, Yamatsuta K, Tokuda N, Takeuchi J, Seko T, Nakagawa H, Miyata N.. (2012) Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors.. J Med Chem, 55 (12): (5760-5773). [PMID:22642300] [10.1021/jm3002108]
55. Wong JC, Tang G, Wu X, Liang C, Zhang Z, Guo L, Peng Z, Zhang W, Lin X, Wang Z, Mei J, Chen J, Pan S, Zhang N, Liu Y, Zhou M, Feng L, Zhao W, Li S, Zhang C, Zhang M, Rong Y, Jin TG, Zhang X, Ren S, Ji Y, Zhao R, She J, Ren Y, Xu C, Chen D, Cai J, Shan S, Pan D, Ning Z, Lu X, Chen T, He Y, Chen L.. (2012) Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.. J Med Chem, 55 (20): (8903-8925). [PMID:23061376] [10.1021/jm3011838]
56. Suzuki T, Ota Y, Ri M, Bando M, Gotoh A, Itoh Y, Tsumoto H, Tatum PR, Mizukami T, Nakagawa H, Iida S, Ueda R, Shirahige K, Miyata N.. (2012) Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.. J Med Chem, 55 (22): (9562-9575). [PMID:23116147] [10.1021/jm300837y]
57. Choi SE, Pflum MK.. (2012) The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.. Bioorg Med Chem Lett, 22 (23): (7084-7086). [PMID:23089527] [10.1016/j.bmcl.2012.09.093]
58. Zhang Y, Yang P, Chou CJ, Liu C, Wang X, Xu W.. (2013) Development of N-Hydroxycinnamamide-Based Histone Deacetylase Inhibitors with Indole-Containing Cap Group.. ACS Med Chem Lett, 4 (2): (235-238). [PMID:23493449] [10.1021/ml300366t]
59. Guerrant W, Patil V, Canzoneri JC, Yao LP, Hood R, Oyelere AK.. (2013) Dual-acting histone deacetylase-topoisomerase I inhibitors.. Bioorg Med Chem Lett, 23 (11): (3283-3287). [PMID:23622981] [10.1016/j.bmcl.2013.03.108]
60. Ko KS, Steffey ME, Brandvold KR, Soellner MB.. (2013) Development of a chimeric c-Src kinase and HDAC inhibitor.. ACS Med Chem Lett, 4 (8): (779-783). [PMID:24015327] [10.1021/ml400175d]
61. Abdel-Magid AF.. (2013) Histone Deacetylase 4 (HDAC4) Inhibitors: A Promising Treatment for Huntington's Disease.. ACS Med Chem Lett, 4 (8): (692-693). [PMID:24900734] [10.1021/ml4002216]
62. Nam NH, Huong TL, Dung do TM, Dung PT, Oanh DT, Quyen D, Thao le T, Park SH, Kim KR, Han BW, Yun J, Kang JS, Kim Y, Han SB.. (2013) Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.. Eur J Med Chem, 70 (477-486). [PMID:24185378] [10.1016/j.ejmech.2013.10.045]
63. Bürli RW, Luckhurst CA, Aziz O, Matthews KL, Yates D, Lyons KA, Beconi M, McAllister G, Breccia P, Stott AJ, Penrose SD, Wall M, Lamers M, Leonard P, Müller I, Richardson CM, Jarvis R, Stones L, Hughes S, Wishart G, Haughan AF, O'Connell C, Mead T, McNeil H, Vann J, Mangette J, Maillard M, Beaumont V, Munoz-Sanjuan I, Dominguez C.. (2013) Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.. J Med Chem, 56 (24): (9934-9954). [PMID:24261862] [10.1021/jm4011884]
64. Wambua MK, Nalawansha DA, Negmeldin AT, Pflum MK.. (2014) Mutagenesis studies of the 14 Å internal cavity of histone deacetylase 1: insights toward the acetate-escape hypothesis and selective inhibitor design.. J Med Chem, 57 (3): (642-650). [PMID:24405391] [10.1021/jm401837e]
65. Sharma SK, Hazeldine S, Crowley ML, Hanson A, Beattie R, Varghese S, Senanayake TM, Hirata A, Hirata F, Huang Y, Wu Y, Steinbergs N, Murray-Stewart T, Bytheway I, Casero RA, Woster PM.. (2012) Polyamine-based small molecule epigenetic modulators.. Medchemcomm, 3 (1): (14-21). [PMID:23293738] [10.1039/c1md00220a]
66. Wang C, Flemming CJ, Cheng YQ.. (2012) Discovery and activity profiling of thailandepsins A through F, potent histone deacetylase inhibitors, from Burkholderia thailandensis E264.. Medchemcomm, 3 (8): (976-981). [PMID:23997923] [10.1039/c2md20024d]
67. Li X, Inks ES, Li X, Hou J, Chou CJ, Zhang J, Jiang Y, Zhang Y, Xu W.. (2014) Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.. J Med Chem, 57 (8): (3324-3341). [PMID:24694055] [10.1021/jm401877m]
68. Cincinelli R, Musso L, Giannini G, Zuco V, De Cesare M, Zunino F, Dallavalle S.. (2014) Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.. Eur J Med Chem, 79 (251-259). [PMID:24742384] [10.1016/j.ejmech.2014.04.021]
69. Ononye SN, Vanheyst MD, Giardina C, Wright DL, Anderson AC.. (2014) Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.. Bioorg Med Chem, 22 (7): (2188-2193). [PMID:24613456] [10.1016/j.bmc.2014.02.018]
70. Lee HY, Tsai AC, Chen MC, Shen PJ, Cheng YC, Kuo CC, Pan SL, Liu YM, Liu JF, Yeh TK, Wang JC, Chang CY, Chang JY, Liou JP.. (2014) Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.. J Med Chem, 57 (10): (4009-4022). [PMID:24766560] [10.1021/jm401899x]
71. Bhansali P, Hanigan CL, Perera L, Casero RA, Tillekeratne LM.. (2014) Synthesis and biological evaluation of largazole analogues with modified surface recognition cap groups.. Eur J Med Chem, 86 (528-541). [PMID:25203782] [10.1016/j.ejmech.2014.09.009]
72. Tang G, Wong JC, Zhang W, Wang Z, Zhang N, Peng Z, Zhang Z, Rong Y, Li S, Zhang M, Yu L, Feng T, Zhang X, Wu X, Wu JZ, Chen L.. (2014) Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.. J Med Chem, 57 (19): (8026-8034). [PMID:25238284] [10.1021/jm5008962]
73. Valente S, Trisciuoglio D, De Luca T, Nebbioso A, Labella D, Lenoci A, Bigogno C, Dondio G, Miceli M, Brosch G, Del Bufalo D, Altucci L, Mai A.. (2014) 1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.. J Med Chem, 57 (14): (6259-6265). [PMID:24972008] [10.1021/jm500303u]
74. Du L, Risinger AL, King JB, Powell DR, Cichewicz RH.. (2014) A potent HDAC inhibitor, 1-alaninechlamydocin, from a Tolypocladium sp. induces G2/M cell cycle arrest and apoptosis in MIA PaCa-2 cells.. J Nat Prod, 77 (7): (1753-1757). [PMID:24999749] [10.1021/np500387h]
75. Duan W, Li J, Inks ES, Chou CJ, Jia Y, Chu X, Li X, Xu W, Zhang Y.. (2015) Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.. J Med Chem, 58 (10): (4325-4338). [PMID:25906087] [10.1021/acs.jmedchem.5b00317]
76. Fredenhagen A, Kittelmann M, Oberer L, Kuhn A, Kühnöl J, Délémonté T, Aichholz R, Wang P, Atadja P, Shultz MD.. (2012) Biocatalytic synthesis and structure elucidation of cyclized metabolites of the deacetylase inhibitor panobinostat (LBH589).. Drug Metab Dispos, 40 (5): (1041-1050). [PMID:22344701] [10.1124/dmd.111.043620]
77. Daniel KB, Sullivan ED, Chen Y, Chan JC, Jennings PA, Fierke CA, Cohen SM.. (2015) Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.. J Med Chem, 58 (11): (4812-4821). [PMID:25974739] [10.1021/acs.jmedchem.5b00539]
78. Ashwini N, Garg M, Mohan CD, Fuchs JE, Rangappa S, Anusha S, Swaroop TR, Rakesh KS, Kanojia D, Madan V, Bender A, Koeffler HP, Basappa, Rangappa KS.. (2015) Synthesis of 1,2-benzisoxazole tethered 1,2,3-triazoles that exhibit anticancer activity in acute myeloid leukemia cell lines by inhibiting histone deacetylases, and inducing p21 and tubulin acetylation.. Bioorg Med Chem, 23 (18): (6157-6165). [PMID:26299825] [10.1016/j.bmc.2015.07.069]
79. Muthyala R, Shin WS, Xie J, Sham YY.. (2015) Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.. Bioorg Med Chem Lett, 25 (19): (4320-4324). [PMID:26264503] [10.1016/j.bmcl.2015.07.065]
80. Yao Y, Tu Z, Liao C, Wang Z, Li S, Yao H, Li Z, Jiang S.. (2015) Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.. J Med Chem, 58 (19): (7672-7680). [PMID:26331334] [10.1021/acs.jmedchem.5b01044]
81. Peng FW, Wu TT, Ren ZW, Xue JY, Shi L.. (2015) Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase.. Bioorg Med Chem Lett, 25 (22): (5137-5141). [PMID:26475519] [10.1016/j.bmcl.2015.10.006]
82. Ling Y, Xu C, Luo L, Cao J, Feng J, Xue Y, Zhu Q, Ju C, Li F, Zhang Y, Zhang Y, Ling X.. (2015) Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.. J Med Chem, 58 (23): (9214-9227). [PMID:26555243] [10.1021/acs.jmedchem.5b01052]
83. Yang Z, Wang T, Wang F, Niu T, Liu Z, Chen X, Long C, Tang M, Cao D, Wang X, Xiang W, Yi Y, Ma L, You J, Chen L.. (2016) Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.. J Med Chem, 59 (4): (1455-1470). [PMID:26443078] [10.1021/acs.jmedchem.5b01342]
84. Cincinelli R, Zwick V, Musso L, Zuco V, De Cesare M, Zunino F, Simoes-Pires C, Nurisso A, Giannini G, Cuendet M, Dallavalle S.. (2016) Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.. Eur J Med Chem, 112 (99-105). [PMID:26890116] [10.1016/j.ejmech.2016.02.001]
85. Yoo J, Kim SJ, Son D, Seo H, Baek SY, Maeng CY, Lee C, Kim IS, Jung YH, Lee SM, Park HJ.. (2016) Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.. Eur J Med Chem, 116 (126-135). [PMID:27060764] [10.1016/j.ejmech.2016.03.046]
86. Wagner FF, Weïwer M, Steinbacher S, Schomburg A, Reinemer P, Gale JP, Campbell AJ, Fisher SL, Zhao WN, Reis SA, Hennig KM, Thomas M, Müller P, Jefson MR, Fass DM, Haggarty SJ, Zhang YL, Holson EB.. (2016) Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors.. Bioorg Med Chem, 24 (18): (4008-4015). [PMID:27377864] [10.1016/j.bmc.2016.06.040]
87. Stenzel K, Hamacher A, Hansen FK, Gertzen CGW, Senger J, Marquardt V, Marek L, Marek M, Romier C, Remke M, Jung M, Gohlke H, Kassack MU, Kurz T.. (2017) Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.. J Med Chem, 60 (13): (5334-5348). [PMID:28581289] [10.1021/acs.jmedchem.6b01538]
88. Li X, Zhang Y, Jiang Y, Wu J, Inks ES, Chou CJ, Gao S, Hou J, Ding Q, Li J, Wang X, Huang Y, Xu W.. (2017) Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.. Eur J Med Chem, 134 (185-206). [PMID:28415009] [10.1016/j.ejmech.2017.03.069]
89. Li X, Peterson YK, Inks ES, Himes RA, Li J, Zhang Y, Kong X, Chou CJ.. (2018) Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status.. J Med Chem, 61 (6): (2589-2603). [PMID:29499113] [10.1021/acs.jmedchem.8b00136]
90. Lee HY, Nepali K, Huang FI, Chang CY, Lai MJ, Li YH, Huang HL, Yang CR, Liou JP.. (2018) (N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.. J Med Chem, 61 (3): (905-917). [PMID:29304284] [10.1021/acs.jmedchem.7b01404]
91. De Vreese R, D'hooghe M.. (2017) Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.. Eur J Med Chem, 135 (174-195). [PMID:28453994] [10.1016/j.ejmech.2017.04.013]
92. Lee HY, Lee JF, Kumar S, Wu YW, HuangFu WC, Lai MJ, Li YH, Huang HL, Kuo FC, Hsiao CJ, Cheng CC, Yang CR, Liou JP.. (2017) 3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.. Eur J Med Chem, 125 (1268-1278). [PMID:27886544] [10.1016/j.ejmech.2016.11.033]
93. Yang K, Song Y, Xie H, Wu H, Wu YT, Leisten ED, Tang W.. (2018) Development of the first small molecule histone deacetylase 6 (HDAC6) degraders.. Bioorg Med Chem Lett, 28 (14): (2493-2497). [PMID:29871848] [10.1016/j.bmcl.2018.05.057]
94. Hsieh HY, Chuang HC, Shen FH, Detroja K, Hsin LW, Chen CS.. (2017) Targeting breast cancer stem cells by novel HDAC3-selective inhibitors.. Eur J Med Chem, 140 (42-51). [PMID:28923385] [10.1016/j.ejmech.2017.08.069]
95. Duan YC, Ma YC, Qin WP, Ding LN, Zheng YC, Zhu YL, Zhai XY, Yang J, Ma CY, Guan YY.. (2017) Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.. Eur J Med Chem, 140 (392-402). [PMID:28987602] [10.1016/j.ejmech.2017.09.038]
96. Zagni C, Pistarà V, Oliveira LA, Castilho RM, Romeo G, Chiacchio U, Rescifina A.. (2017) Serendipitous discovery of potent human head and neck squamous cell carcinoma anti-cancer molecules: A fortunate failure of a rational molecular design.. Eur J Med Chem, 141 (188-196). [PMID:29031066] [10.1016/j.ejmech.2017.09.075]
97. Zhang Y, Yan J, Yao TP.. (2017) Discovery of a fluorescent probe with HDAC6 selective inhibition.. Eur J Med Chem, 141 (596-602). [PMID:29102179] [10.1016/j.ejmech.2017.10.022]
98. Chao SW, Chen LC, Yu CC, Liu CY, Lin TE, Guh JH, Wang CY, Chen CY, Hsu KC, Huang WJ.. (2018) Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.. Eur J Med Chem, 143 (792-805). [PMID:29223096] [10.1016/j.ejmech.2017.11.092]
99. Huang Y, Dong G, Li H, Liu N, Zhang W, Sheng C.. (2018) Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.. J Med Chem, 61 (14): (6056-6074). [PMID:29940115] [10.1021/acs.jmedchem.8b00393]
100. Zang J, Liang X, Huang Y, Jia Y, Li X, Xu W, Chou CJ, Zhang Y.. (2018) Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.. J Med Chem, 61 (12): (5304-5322). [PMID:29787262] [10.1021/acs.jmedchem.8b00384]
101. Rabal O, Sánchez-Arias JA, Cuadrado-Tejedor M, de Miguel I, Pérez-González M, García-Barroso C, Ugarte A, Estella-Hermoso de Mendoza A, Sáez E, Espelosin M, Ursua S, Haizhong T, Wei W, Musheng X, Garcia-Osta A, Oyarzabal J.. (2018) Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.. Eur J Med Chem, 150 (506-524). [PMID:29549837] [10.1016/j.ejmech.2018.03.005]
102. Granatosky EA, DiPrimio N, Pickering JRE, Stevens DC, Perlstein EO, Taylor RE.. (2018) GEX1A, a Polyketide from Streptomyces chromofuscus, Corrects the Cellular Defects Associated with Niemann-Pick Type C1 in Human Fibroblasts.. J Nat Prod, 81 (9): (2018-2025). [PMID:30188717] [10.1021/acs.jnatprod.8b00314]
103. Ojha R, Huang HL, HuangFu WC, Wu YW, Nepali K, Lai MJ, Su CJ, Sung TY, Chen YL, Pan SL, Liou JP.. (2018) 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.. Eur J Med Chem, 150 (667-677). [PMID:29567459] [10.1016/j.ejmech.2018.03.006]
104. Negmeldin AT, Knoff JR, Pflum MKH.. (2018) The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.. Eur J Med Chem, 143 (1790-1806). [PMID:29150330] [10.1016/j.ejmech.2017.10.076]
105. Garsi JB, Sernissi L, Vece V, Hanessian S, McCracken AN, Simitian G, Edinger AL.. (2018) In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.. Eur J Med Chem, 159 (217-242). [PMID:30292898] [10.1016/j.ejmech.2018.09.043]
106. Maruta H, Ahn MR.. (2017) From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy.. Eur J Med Chem, 142 (229-243). [PMID:28814374] [10.1016/j.ejmech.2017.07.043]
107. Liang T, Hou X, Zhou Y, Yang X, Fang H.. (2019) Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.. ACS Med Chem Lett, 10 (8): (1122-1127). [PMID:31413795] [10.1021/acsmedchemlett.9b00084]
108. Wu H, Yang K, Zhang Z, Leisten ED, Li Z, Xie H, Liu J, Smith KA, Novakova Z, Barinka C, Tang W.. (2019) Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.. J Med Chem, 62 (15): (7042-7057). [PMID:31271281] [10.1021/acs.jmedchem.9b00516]
109. Soumyanarayanan U, Ramanujulu PM, Mustafa N, Haider S, Fang Nee AH, Tong JX, Tan KSW, Chng WJ, Dymock BW.. (2019) Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.. Eur J Med Chem, 184 (111755-111755). [PMID:31627059] [10.1016/j.ejmech.2019.111755]
110. Bouchut A, Rotili D, Pierrot C, Valente S, Lafitte S, Schultz J, Hoglund U, Mazzone R, Lucidi A, Fabrizi G, Pechalrieu D, Arimondo PB, Skinner-Adams TS, Chua MJ, Andrews KT, Mai A, Khalife J.. (2019) Identification of novel quinazoline derivatives as potent antiplasmodial agents.. Eur J Med Chem, 161 (277-291). [PMID:30366254] [10.1016/j.ejmech.2018.10.041]
111. Krieger V, Hamacher A, Cao F, Stenzel K, Gertzen CGW, Schäker-Hübner L, Kurz T, Gohlke H, Dekker FJ, Kassack MU, Hansen FK.. (2019) Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.. J Med Chem, 62 (24): (11260-11279). [PMID:31762274] [10.1021/acs.jmedchem.9b01489]
112. Wan Y, Li Y, Yan C, Yan M, Tang Z.. (2019) Indole: A privileged scaffold for the design of anti-cancer agents.. Eur J Med Chem, 183 (111691-111691). [PMID:31536895] [10.1016/j.ejmech.2019.111691]
113. Pan Z, Li X, Wang Y, Jiang Q, Jiang L, Zhang M, Zhang N, Wu F, Liu B, He G.. (2020) Discovery of Thieno[2,3-d]pyrimidine-Based Hydroxamic Acid Derivatives as Bromodomain-Containing Protein 4/Histone Deacetylase Dual Inhibitors Induce Autophagic Cell Death in Colorectal Carcinoma Cells.. J Med Chem, 63 (7): (3678-3700). [PMID:32153186] [10.1021/acs.jmedchem.9b02178]
114. Han G, Liu N, Li C, Tu J, Li Z, Sheng C.. (2020) Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.. J Med Chem, 63 (10): (5341-5359). [PMID:32347094] [10.1021/acs.jmedchem.0c00102]
115. Liang X, Zang J, Li X, Tang S, Huang M, Geng M, Chou CJ, Li C, Cao Y, Xu W, Liu H, Zhang Y.. (2019) Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.. J Med Chem, 62 (8): (3898-3923). [PMID:30901208] [10.1021/acs.jmedchem.8b01597]
116. Yang Z, Shen M, Tang M, Zhang W, Cui X, Zhang Z, Pei H, Li Y, Hu M, Bai P, Chen L.. (2019) Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.. Eur J Med Chem, 178 (116-130). [PMID:31177073] [10.1016/j.ejmech.2019.05.089]
117. Asfaha Y, Schrenk C, Alves Avelar LA, Hamacher A, Pflieger M, Kassack MU, Kurz T.. (2019) Recent advances in class IIa histone deacetylases research.. Bioorg Med Chem, 27 (22): (115087-115087). [PMID:31561937] [10.1016/j.bmc.2019.115087]
118. Vögerl K, Ong N, Senger J, Herp D, Schmidtkunz K, Marek M, Müller M, Bartel K, Shaik TB, Porter NJ, Robaa D, Christianson DW, Romier C, Sippl W, Jung M, Bracher F.. (2019) Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.. J Med Chem, 62 (3): (1138-1166). [PMID:30645113] [10.1021/acs.jmedchem.8b01090]
119. Ling Y, Li Y, Zhu R, Qian J, Liu J, Gao W, Meng C, Miao J, Xiong B, Qiu X, Ling C, Dai H, Zhang Y.. (2019) Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.. J Nat Prod, 82 (6): (1442-1450). [PMID:31120744] [10.1021/acs.jnatprod.8b00843]
120. Lai MJ, Ojha R, Lin MH, Liu YM, Lee HY, Lin TE, Hsu KC, Chang CY, Chen MC, Nepali K, Chang JY, Liou JP.. (2019) 1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.. Eur J Med Chem, 162 (612-630). [PMID:30476825] [10.1016/j.ejmech.2018.10.066]
121. Bouchet S, Linot C, Ruzic D, Agbaba D, Fouchaq B, Roche J, Nikolic K, Blanquart C, Bertrand P.. (2019) Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.. ACS Med Chem Lett, 10 (6): (863-868). [PMID:31223439] [10.1021/acsmedchemlett.8b00440]
122. Shouksmith AE, Shah F, Grimard ML, Gawel JM, Raouf YS, Geletu M, Berger-Becvar A, de Araujo ED, Luchman HA, Heaton WL, Bakhshinyan D, Adile AA, Venugopal C, O'Hare T, Deininger MW, Singh SK, Konieczny SF, Weiss S, Fishel ML, Gunning PT.. (2019) Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer.. J Med Chem, 62 (5): (2651-2665). [PMID:30776234] [10.1021/acs.jmedchem.8b01957]
123. Wolff B, Jänsch N, Sugiarto WO, Frühschulz S, Lang M, Altintas R, Oehme I, Meyer-Almes FJ.. (2019) Synthesis and structure activity relationship of 1, 3-benzo-thiazine-2-thiones as selective HDAC8 inhibitors.. Eur J Med Chem, 184 (111756-111756). [PMID:31630054] [10.1016/j.ejmech.2019.111756]
124. Chen Y, Yuan X, Zhang W, Tang M, Zheng L, Wang F, Yan W, Yang S, Wei Y, He J, Chen L.. (2019) Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors as a Promising Strategy for Cancer Therapy.. J Med Chem, 62 (3): (1577-1592). [PMID:30629434] [10.1021/acs.jmedchem.8b01825]
125. Vergani B, Sandrone G, Marchini M, Ripamonti C, Cellupica E, Galbiati E, Caprini G, Pavich G, Porro G, Rocchio I, Lattanzio M, Pezzuto M, Skorupska M, Cordella P, Pagani P, Pozzi P, Pomarico R, Modena D, Leoni F, Perego R, Fossati G, Steinkühler C, Stevenazzi A.. (2019) Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation.. J Med Chem, 62 (23): (10711-10739). [PMID:31710483] [10.1021/acs.jmedchem.9b01194]
126. Song Y, Lim J, Seo YH.. (2019) A novel class of anthraquinone-based HDAC6 inhibitors.. Eur J Med Chem, 164 (263-272). [PMID:30597327] [10.1016/j.ejmech.2018.12.056]
127. Gromek SM, deMayo JA, Maxwell AT, West AM, Pavlik CM, Zhao Z, Li J, Wiemer AJ, Zweifach A, Balunas MJ.. (2016) Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.. Bioorg Med Chem, 24 (21): (5183-5196). [PMID:27614919] [10.1016/j.bmc.2016.08.040]
128. De Simone A, La Pietra V, Betari N, Petragnani N, Conte M, Daniele S, Pietrobono D, Martini C, Petralla S, Casadei R, Davani L, Frabetti F, Russomanno P, Novellino E, Montanari S, Tumiatti V, Ballerini P, Sarno F, Nebbioso A, Altucci L, Monti B, Andrisano V, Milelli A.. (2019) Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease.. ACS Med Chem Lett, 10 (4): (469-474). [PMID:30996781] [10.1021/acsmedchemlett.8b00507]
129. Makino J, Ogasawara R, Kamiya T, Hara H, Mitsugi Y, Yamaguchi E, Itoh A, Adachi T.. (2016) Royal Jelly Constituents Increase the Expression of Extracellular Superoxide Dismutase through Histone Acetylation in Monocytic THP-1 Cells.. J Nat Prod, 79 (4): (1137-1143). [PMID:27049436] [10.1021/acs.jnatprod.6b00037]
130. Asfaha Y, Schrenk C, Alves Avelar LA, Lange F, Wang C, Bandolik JJ, Hamacher A, Kassack MU, Kurz T.. (2020) Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells.. Bioorg Med Chem, 28 (1): (115108-115108). [PMID:31787463] [10.1016/j.bmc.2019.115108]
131. Romanelli A, Stazi G, Fioravanti R, Zwergel C, Di Bello E, Pomella S, Perrone C, Battistelli C, Strippoli R, Tripodi M, Del Bufalo D, Rota R, Trisciuoglio D, Mai A, Valente S.. (2020) Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.. ACS Med Chem Lett, 11 (5): (977-983). [PMID:32435414] [10.1021/acsmedchemlett.0c00014]
132. Terrab L, Rosenker CJ, Johnstone L, Ngo LK, Zhang L, Ware NF, Miller B, Topacio AZ, Sannino S, Brodsky JL, Wipf P.. (2020) Synthesis and Selective Functionalization of Thiadiazine 1,1-Dioxides with Efficacy in a Model of Huntington's Disease.. ACS Med Chem Lett, 11 (5): (984-990). [PMID:32435415] [10.1021/acsmedchemlett.0c00018]
133. Sun W, Chen X, Huang S, Li W, Tian C, Yang S, Li L.. (2020) Discovery of 5-(4-methylpiperazin-1-yl)-2-nitroaniline derivatives as a new class of SIRT6 inhibitors.. Bioorg Med Chem Lett, 30 (16): (127215-127215). [PMID:32631504] [10.1016/j.bmcl.2020.127215]
134. Chen X, Sun W, Huang S, Zhang H, Lin G, Li H, Qiao J, Li L, Yang S.. (2020) Discovery of Potent Small-Molecule SIRT6 Activators: Structure-Activity Relationship and Anti-Pancreatic Ductal Adenocarcinoma Activity.. J Med Chem, 63 (18): (10474-10495). [PMID:32787077] [10.1021/acs.jmedchem.0c01183]
135. Wang XX,Wan RZ,Liu ZP. (2018) Recent advances in the discovery of potent and selective HDAC6 inhibitors.. Eur J Med Chem, 143 (1406-1418). [PMID:29133060] [10.1016/j.ejmech.2017.10.040]
136. Almaliti J,Al-Hamashi AA,Negmeldin AT,Hanigan CL,Perera L,Pflum MK,Casero RA,Tillekeratne LM. (2016) Largazole Analogues Embodying Radical Changes in the Depsipeptide Ring: Development of a More Selective and Highly Potent Analogue.. J Med Chem, 59 (23): (10642-10660). [PMID:27809521] [10.1021/acs.jmedchem.6b01271]
137. Runfola M,Sestito S,Bellusci L,La Pietra V,D'Amore VM,Kowalik MA,Chiellini G,Gul S,Perra A,Columbano A,Marinelli L,Novellino E,Rapposelli S. (2020) Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.. Eur J Med Chem, 188 (112006-112006). [PMID:31931337] [10.1016/j.ejmech.2019.112006]
138. Ojha R,Nepali K,Chen CH,Chuang KH,Wu TY,Lin TE,Hsu KC,Chao MW,Lai MJ,Lin MH,Huang HL,Chang CD,Pan SL,Chen MC,Liou JP. (2020) Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.. Eur J Med Chem, 190 (112086-112086). [PMID:32058238] [10.1016/j.ejmech.2020.112086]
139. Tseng HJ,Lin MH,Shiao YJ,Yang YC,Chu JC,Chen CY,Chen YY,Lin TE,Su CJ,Pan SL,Chen LC,Wang CY,Hsu KC,Huang WJ. (2020) Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.. Eur J Med Chem, 192 (112193-112193). [PMID:32151835] [10.1016/j.ejmech.2020.112193]
140. Chen D,Soh CK,Goh WH,Wang H. (2018) Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.. J Med Chem, 61 (4.0): (1552-1575). [PMID:29360358] [10.1021/acs.jmedchem.7b01465]
141. Gawel JM,Shouksmith AE,Raouf YS,Nawar N,Toutah K,Bukhari S,Manaswiyoungkul P,Olaoye OO,Israelian J,Radu TB,Cabral AD,Sina D,Sedighi A,de Araujo ED,Gunning PT. (2020) PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.. Eur J Med Chem, 201 (112411-112411). [PMID:32615502] [10.1016/j.ejmech.2020.112411]
142. Reßing N,Sönnichsen M,Osko JD,Schöler A,Schliehe-Diecks J,Skerhut A,Borkhardt A,Hauer J,Kassack MU,Christianson DW,Bhatia S,Hansen FK. (2020) Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.. J Med Chem, 63 (18): (10339-10351). [PMID:32803970] [10.1021/acs.jmedchem.9b01888]
143. Zhao L,Fan T,Shi Z,Ding C,Zhang C,Yuan Z,Sun Q,Tan C,Chu B,Jiang Y. (2021) Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR mutant cell lines.. Eur J Med Chem, 213 (113173-113173). [PMID:33493830] [10.1016/j.ejmech.2021.113173]
144. Singh A,Chang TY,Kaur N,Hsu KC,Yen Y,Lin TE,Lai MJ,Lee SB,Liou JP. (2021) CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.. Eur J Med Chem, 215 (113169-113169). [PMID:33588178] [10.1016/j.ejmech.2021.113169]
145. Tilekar K,Upadhyay N,Hess JD,Macias LH,Mrowka P,Aguilera RJ,Meyer-Almes FJ,Iancu CV,Choe JY,Ramaa CS. (2020) Structure guided design and synthesis of furyl thiazolidinedione derivatives as inhibitors of GLUT 1 and GLUT 4, and evaluation of their anti-leukemic potential.. Eur J Med Chem, 202 (112603-112603). [PMID:32634629] [10.1016/j.ejmech.2020.112603]
146. Yao D,Li C,Jiang J,Huang J,Wang J,He Z,Zhang J. (2020) Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.. Eur J Med Chem, 205 (112648-112648). [PMID:32791401] [10.1016/j.ejmech.2020.112648]
147. Wei M,Xie M,Zhang Z,Wei Y,Zhang J,Pan H,Li B,Wang J,Song Y,Chong C,Zhao R,Wang J,Yu L,Yang G,Yang C. (2020) Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.. Eur J Med Chem, 206 (112677-112677). [PMID:32823005] [10.1016/j.ejmech.2020.112677]
148. Rabal O, San José-Enériz E, Agirre X, Sánchez-Arias JA, de Miguel I, Ordoñez R, Garate L, Miranda E, Sáez E, Vilas-Zornoza A, Pineda-Lucena A, Estella A, Zhang F, Wu W, Xu M, Prosper F, Oyarzabal J.. (2021) Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with In Vivo Efficacy in Multiple Myeloma.. J Med Chem, 64 (6.0): (3392-3426). [PMID:33661013] [10.1021/acs.jmedchem.0c02255]
149. Liang X, Tang S, Liu X, Liu Y, Xu Q, Wang X, Saidahmatov A, Li C, Wang J, Zhou Y, Zhang Y, Geng M, Huang M, Liu H.. (2022) Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors.. J Med Chem, 65 (2.0): (1243-1264). [PMID:33586434] [10.1021/acs.jmedchem.0c02111]
150. Olaoye OO, Watson PR, Nawar N, Geletu M, Sedighi A, Bukhari S, Raouf YS, Manaswiyoungkul P, Erdogan F, Abdeldayem A, Cabral AD, Hassan MM, Toutah K, Shouksmith AE, Gawel JM, Israelian J, Radu TB, Kachhiyapatel N, de Araujo ED, Christianson DW, Gunning PT.. (2021) Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype.. J Med Chem, 64 (5.0): (2691-2704). [PMID:33576627] [10.1021/acs.jmedchem.0c01922]
151. Ohara, O O and 6 more authors.. (1997) Construction and characterization of human brain cDNA libraries suitable for analysis of cDNA clones encoding relatively large proteins.. DNA research : an international journal for rapid publication of reports on genes and genomes, (28): [PMID:9179496]
152. Miska, E A EA and 5 more authors.. (1999) HDAC4 deacetylase associates with and represses the MEF2 transcription factor.. The EMBO journal, (15): [PMID:10487761]
153. Wang, A H AH and 8 more authors.. (1999) HDAC4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor.. Molecular and cellular biology, [PMID:10523670]
154. Wang, A H AH and 7 more authors.. (2000) Regulation of histone deacetylase 4 by binding of 14-3-3 proteins.. Molecular and cellular biology, [PMID:10958686]
155. Franco, P J PJ, Farooqui, M M, Seto, E E and Wei, L N LN.. (2001) The orphan nuclear receptor TR2 interacts directly with both class I and class II histone deacetylases.. Molecular endocrinology (Baltimore, Md.), [PMID:11463856]
156. Zhao, X X and 7 more authors.. (2001) The modular nature of histone deacetylase HDAC4 confers phosphorylation-dependent intracellular trafficking.. The Journal of biological chemistry, (14): [PMID:11470791]
157. McKinsey, T A TA, Zhang, C L CL and Olson, E N EN.. (2001) Identification of a signal-responsive nuclear export sequence in class II histone deacetylases.. Molecular and cellular biology, [PMID:11509672]
158. Kirsh, Olivier O and 10 more authors.. (2002) The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase.. The EMBO journal, (3): [PMID:12032081]
159. Hillier, Ladeana W LW and 121 more authors.. (2005) Generation and annotation of the DNA sequences of human chromosomes 2 and 4.. Nature, (7): [PMID:15815621]
160. Sjöblom, Tobias T and 28 more authors.. (2006) The consensus coding sequences of human breast and colorectal cancers.. Science (New York, N.Y.), (13): [PMID:16959974]
161. Geng, Ling L and 5 more authors.. (2006) Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer.. Cancer research, (1): [PMID:17145876]
162. Little, Gillian H GH, Bai, Yan Y, Williams, Tyisha T and Poizat, Coralie C.. (2007) Nuclear calcium/calmodulin-dependent protein kinase IIdelta preferentially transmits signals to histone deacetylase 4 in cardiac cells.. The Journal of biological chemistry, (9): [PMID:17179159]
163. Barrett, Angela A and 11 more authors.. (2007) Breast cancer associated transcriptional repressor PLU-1/JARID1B interacts directly with histone deacetylases.. International journal of cancer, (15): [PMID:17373667]
164. Dephoure, Noah N and 6 more authors.. (2008) A quantitative atlas of mitotic phosphorylation.. Proceedings of the National Academy of Sciences of the United States of America, (5): [PMID:18669648]
165. Mayya, Viveka V and 7 more authors.. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.. Science signaling, (18): [PMID:19690332]
166. Shao, Yangguang and 7 more authors.. (2010) Involvement of histone deacetylation in MORC2-mediated down-regulation of carbonic anhydrase IX.. Nucleic acids research, [PMID:20110259]
167. Williams, Stephen R SR and 9 more authors.. (2010) Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems.. American journal of human genetics, (13): [PMID:20691407]
168. Rigbolt, Kristoffer T G KT and 9 more authors.. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.. Science signaling, (15): [PMID:21406692]
169. VanderMolen, Karen M; McCulloch, William; Pearce, Cedric J and Oberlies, Nicholas H.. (2011) Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma.. The Journal of antibiotics, [PMID:21587264]
170. Xu, Chao C and 17 more authors.. (2012) Sequence-specific recognition of a PxLPxI/L motif by an ankyrin repeat tumbler lock.. Science signaling, (29): [PMID:22649097]
171. Zhou, Houjiang H and 6 more authors.. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome.. Journal of proteome research, (4): [PMID:23186163]
172. Villavicencio-Lorini, Pablo P and 5 more authors.. (2013) Phenotypic variant of Brachydactyly-mental retardation syndrome in a family with an inherited interstitial 2q37.3 microdeletion including HDAC4.. European journal of human genetics : EJHG, [PMID:23188045]
173. Piton, Amélie A and 20 more authors.. (2014) 20 ans après: a second mutation in MAOA identified by targeted high-throughput sequencing in a family with altered behavior and cognition.. European journal of human genetics : EJHG, [PMID:24169519]
174. Kang, Hyun-Jin HJ and 9 more authors.. (2014) Differential regulation of estrogen receptor α expression in breast cancer cells by metastasis-associated protein 1.. Cancer research, (1): [PMID:24413532]
175. Wheeler, Patricia G PG, Huang, Dongli D and Dai, Zunyan Z.. (2014) Haploinsufficiency of HDAC4 does not cause intellectual disability in all affected individuals.. American journal of medical genetics. Part A, [PMID:24715439]
176. Balasubramanian, Gopalan G and 5 more authors.. (2014) Quinolone-based HDAC inhibitors.. Journal of enzyme inhibition and medicinal chemistry, [PMID:25019596]
177. Wang, Yunfei and 13 more authors.. (2015) Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases.. Chemistry & biology, (19): [PMID:25699604]
178. Nie, Jianyun J and 10 more authors.. (2015) Ankyrin repeats of ANKRA2 recognize a PxLPxL motif on the 3M syndrome protein CCDC8.. Structure (London, England : 1993), (7): [PMID:25752541]
179. Wagner, Florence F FF and 20 more authors.. (2016) An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection.. ACS chemical biology, (19): [PMID:26640968]
180. Wang, Xue X and 8 more authors.. (2017) Design, synthesis, and preliminary bioactivity evaluation of N1 -hydroxyterephthalamide derivatives with indole cap as novel histone deacetylase inhibitors.. Chemical biology & drug design, [PMID:27416889]
181. Seo, Ji Hae JH and 18 more authors.. (2016) ARD1-mediated Hsp70 acetylation balances stress-induced protein refolding and degradation.. Nature communications, (6): [PMID:27708256]
182. Nalawansha, Dhanusha A DA and Pflum, Mary Kay H MK.. (2017) LSD1 Substrate Binding and Gene Expression Are Affected by HDAC1-Mediated Deacetylation.. ACS chemical biology, (20): [PMID:27977115]
183. Zhang, Lei; Zhang, Jian; Jiang, Qixiao; Zhang, Li and Song, Weiguo.. (2018) Zinc binding groups for histone deacetylase inhibitors.. Journal of enzyme inhibition and medicinal chemistry, [PMID:29616828]
184. Zhu, Yiping; Wang, Gary Z; Cingöz, Oya and Goff, Stephen P.. (2018) NP220 mediates silencing of unintegrated retroviral DNA.. Nature, [PMID:30487602]
185. Wakeling, Emma and 16 more authors.. (2021) Missense substitutions at a conserved 14-3-3 binding site in HDAC4 cause a novel intellectual disability syndrome.. HGG advances, (14): [PMID:33537682]
186. Cheng C,Yun F,Ullah S,Yuan Q. (2020) Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.. Eur J Med Chem, 189 (112073-112073). [PMID:31991336] [10.1016/j.ejmech.2020.112073]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

货号 (SKU)	包装规格	是否现货
Ab107057-10μl	10μl	现货
Ab107057-50μl	50μL	现货
Ab107057-100μl	100μL	期货
Ab107057-1ml	1ml	期货

HDAC4 Mouse mAb

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

应用

质检证书（CoA,COO,BSE/TSE 和分析图谱)

技术文档和文章

此产品的引用文献

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器

HDAC4 Mouse mAb

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

应用

质检证书（CoA,COO,BSE/TSE 和分析图谱)

技术文档和文章

相关产品

此产品的引用文献

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器